Nav: Home

Promising results for new acute porphyria treatment

February 07, 2019

Acute porphyria is a group of uncommon diseases that can cause severe, potentially life-threatening attacks of abdominal pain, nausea, vomiting and paralysis. Liver transplantation is currently the only effective treatment available for the most seriously afflicted patients. A clinical trial conducted in collaboration with researchers at Karolinska Institutet in Sweden now shows that a new drug candidate can prevent attacks in these patients. The study is published in The New England Journal of Medicine.

Porphyria is caused by different inherited disorders in the synthesis of heme, the oxygen-binding component of red blood cells. Heme is also necessary for the metabolism of certain drugs and hormones by the liver. When the liver is unable to synthesise heme properly, toxic substances called porphyrin metabolites accumulate in the body, resulting in acute porphyria attacks. A small group of porphyria patients suffer recurrent acute attacks, which cause them chronic debilitating symptoms requiring constant hospital care.

Acute intermittent porphyria (AIP) is the most common form of acute porphyria. Patients suffering from acute attacks are treated using an infusion containing a form of heme called hemin, which suppresses the formation of the toxic metabolites.

"Hemin has saved the lives of many patients and will continue to be important, but it's only for acute treatment," says the study's lead author Eliane Sardh, researcher at the Department of Molecular Medicine and Surgery, Karolinska Institutet, and consultant at Karolinska University Hospital. "For patients with recurrent attacks, no other curative treatment is available than liver transplantation."

However, the new drug candidate givosiran, developed by Alnylam Pharmaceuticals, has shown promising results in a clinical phase I study in 40 patients. The study has been conducted in close, long-standing collaboration with Porphyria Centre Sweden, which has also provided the majority of the patients.

The administration of givosiran reduced the number of acute attacks in the patients by up to 79 per cent, and the need for hemin decreased by up to 83 per cent. Most of the reported side effects were mild or moderate, and no clear link was observed between adverse reactions and dose. Severe adverse reactions were reported in six patients, including one death that was deemed unrelated to givosiran.

The drug candidate is based on a natural method of inhibiting gene expression called RNA interference (RNAi).

"Givosiran down-regulates ALAS1, the key regulator of the hepatic heme synthesis pathway, which reduces the toxic metabolites without the use of hemin," says Dr Sardh. "It also has a lasting effect of at least one month, which gives us an effective means of preventing acute attacks in seriously afflicted porphyria patients who have limited treatment options."

The drug candidate has been given PRIME and Breakthrough Designation by the European Medicines Agency and the U.S. Food and Drug Administration, which in speeding up the review process could mean that the drug may be available by early 2020. The patients that took part in the phase I study will remain on givosiran in a combined phase I/II study, and complete results from a phase III study in 94 patients from around the world are expected in the spring of 2019.
-end-
The study design and study research was conducted by Karolinska University Hospital, Karolinska Institutet, Porphyria Centre Sweden, the Icahn School of Medicine at Mount Sinai (New York), King's College Hospital (London), the University of California (San Francisco), the University of Utah (Salt Lake City), Wake Forest University (Winston-Salem), and the University of Texas Medical Branch (Galveston). It was financed by Alnylam Pharmaceuticals.

Publication: "Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria". Eliane Sardh, Pauline Harper, Manisha Balwani, Penelope Stein, David Rees, D. Montgomery Bissell, Robert Desnick, Charles Parker, John Phillips, Herbert L. Bonkovsky, Daphne Vassiliou, Craig Penz, Amy Chan-Daniels, Qiuling He, William Querbes, Kevin Fitzgerald, Jae B. Kim, Pushkal Garg, Akshay Vaishnaw, Amy R. Simon and Karl E. Anderson. The New England Journal of Medicine, online 6 February 2019, doi: 10.1056/NEJMoa1807838.

Karolinska Institutet

Related Abdominal Pain Articles:

Advances in the detection of the postoperative progress of abdominal aortic aneurysm
A study published in Frontiers in Bioengineering and Biotechnology by a team of researchers from BCN MedTech with the VICOMTech Foundation in San Sebastian, the BioDonostia Health Research Institute and Donostia University Hospital, offers a promising methodology for post-operative CTA time-series registration and subsequent aneurysm biomechanical strain analysis, which correlates with the patient's long-term prognosis.
New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.
With abdominal etching, plastic surgeons help patients get 'six-pack abs'
Even with a good diet and workout routine, some men and women have trouble getting the toned abdominal appearance they want.
App predicts risk of developing hernia following abdominal surgery
A new app can predict the likelihood that a patient will develop an incisional hernia following abdominal surgery, using big data to potentially help address a problem effects one out of every eight of these surgical patients.
Researchers uncover new cause of abdominal aortic aneurysm
Researchers have discovered that a family of lipids (fats) contribute to the development of a serious aortic disease, by driving clotting in the blood vessel wall.
Abdominal aortic calcification may signal future heart attack
Computed tomography (CT)-based measures of calcification in the abdominal aorta are strong predictors of heart attacks and other adverse cardiovascular events -- stronger even than the widely used Framingham risk score, according to a new study.
A simple measurement of abdominal obesity
In obesity research, the body mass index (BMI) has been traditionally used to determine if an individual is normal weight, underweight, overweight or obese.
Abdominal obesity linked to lower urinary tract symptoms
In a recent LUTS study, men with central (or abdominal) obesity were at increased risk of experiencing lower urinary tract symptoms, and increased waist-to-hip ratio was associated with worsened straining and weak stream.
Treating menopause symptoms reduces abdominal fat tissue
Women who undergo hormone therapy to relieve menopausal symptoms tend to have less fat tissue, particularly in the abdomen, than other menopausal women, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
General emergency departments use CT to diagnose abdominal pain in children more often
A child with non-traumatic abdominal pain, a common symptom of appendicitis, is more likely to receive a computed tomography (CT) scan in a general emergency department (ED) than if he or she visited a pediatric emergency department, according to a study published in Pediatrics.
More Abdominal Pain News and Abdominal Pain Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at Radiolab.org/donate.